Cover Image
市場調查報告書

胎盤成長因子:開發中產品分析

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 398837
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
胎盤成長因子:開發中產品分析 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 67 Pages
簡介

本報告提供以胎盤成長因子為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胎盤成長因子 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alteogen Inc.
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical, Inc.
  • Formycon AG
  • Regeneron Pharmaceuticals Inc
  • ThromboGenics NV

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1018TDB

Summary:

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cancer Anorexia-Cachexia Syndrome - Overview
  • Cancer Anorexia-Cachexia Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
  • Abreos Biosciences Inc
  • Acacia Pharma Ltd
  • Aeterna Zentaris Inc
  • Incyte Corp
  • Lakewood-Amedex Inc
  • Novartis AG
  • Paradigm Biopharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Viking Therapeutics Inc
  • Zeria Pharmaceutical Co Ltd
  • Cancer Anorexia-Cachexia Syndrome - Drug Profiles
  • (formoterol fumarate + megestrol acetate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • anamorelin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AV-380 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVGN-7 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-1889 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DLN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ENERGIF-706 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Foxo1-nRNA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IP-1510 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • macimorelin acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NEO-1940 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00433412 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ruxolitinib phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides for Cancer Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TCMCB-07 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VK-5211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Z-505 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects
  • Cancer Anorexia-Cachexia Syndrome - Discontinued Products
  • Cancer Anorexia-Cachexia Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
  • Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
  • Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
  • Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
  • Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
  • Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
  • Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
  • Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
  • Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
  • Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
  • Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
  • Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
  • Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
  • Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
  • Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview 6
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development 7
  • Products under Development by Stage of Development 7
  • Products under Development by Therapy Area 8
  • Products under Development by Indication 9
  • Products under Development by Companies 10
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment 13
  • Assessment by Mechanism of Action 13
  • Assessment by Route of Administration 14
  • Assessment by Molecule Type 16
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development 18
  • Alteogen Inc 18
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd 18
  • Formycon AG 18
  • Lupin Ltd 19
  • Regeneron Pharmaceuticals Inc 20
  • ThromboGenics NV 20
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles 22
  • (aflibercept + nesvacumab) - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • aflibercept - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • aflibercept biosimilar - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • aflibercept biosimilar - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • aflibercept biosimilar - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • aflibercept SR - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • conbercept - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • SL-186 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • SL-188 - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • THR-317 - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • ziv-aflibercept - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products 52
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products 53
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones 54
  • Featured News & Press Releases 54
  • Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54
  • May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55
  • May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56
  • Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57
  • Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58
  • Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58
  • Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59
  • May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60
  • May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61
  • Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62
  • Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62
  • Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 63
  • Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64
  • Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64
  • Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65
  • Appendix 66
  • Methodology 66
  • Coverage 66
  • Secondary Research 66
  • Primary Research 66
  • Expert Panel Validation 66
  • Contact Us 66
  • Disclaimer 67

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017 7
  • Number of Products under Development by Therapy Areas, H2 2017 8
  • Number of Products under Development by Indication, H2 2017 9
  • Number of Products under Development by Companies, H2 2017 10
  • Products under Development by Companies, H2 2017 11
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
  • Number of Products by Stage and Mechanism of Actions, H2 2017 13
  • Number of Products by Stage and Route of Administration, H2 2017 15
  • Number of Products by Stage and Molecule Type, H2 2017 17
  • Pipeline by Alteogen Inc, H2 2017 18
  • Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18
  • Pipeline by Formycon AG, H2 2017 19
  • Pipeline by Lupin Ltd, H2 2017 19
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20
  • Pipeline by ThromboGenics NV, H2 2017 21
  • Dormant Projects, H2 2017 52
  • Discontinued Products, H2 2017 53

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017 7
  • Number of Products under Development by Therapy Areas, H2 2017 8
  • Number of Products under Development by Top 10 Indications, H2 2017 9
  • Number of Products by Stage and Mechanism of Actions, H2 2017 13
  • Number of Products by Routes of Administration, H2 2017 14
  • Number of Products by Stage and Routes of Administration, H2 2017 14
  • Number of Products by Molecule Types, H2 2017 16
  • Number of Products by Stage and Molecule Types, H2 2017 16
Back to Top